Bridgeway Capital Management’s Metagenomi Therapeutics MGX Stock Holding History

Bridgeway Capital Management’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$476K	Buy	400,300 +4,500	+1%	+$6.02K	0.01%	856
2026 Q1	$530K	Hold	395,800	–	–	0.01%	818
2025 Q4	$641K	Buy	395,800 +200,000	+102%	+$433K	0.01%	778
2025 Q3	$464K	Buy	195,800 +97,100	+98%	+$197K	0.01%	819
2025 Q2	$146K	Hold	98,700	–	–	﹤0.01%	1017
2025 Q1	$134K	Buy	98,700 +6,500	+7%	+$15.5K	﹤0.01%	992
2024 Q4	$333K	Hold	92,200	–	–	0.01%	899
2024 Q3	$200K	Buy	+92,200	New	+$320K	﹤0.01%	1067

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Bridgeway Capital Management's MGX Position: Q2 2026 in Review

Bridgeway Capital Management increased its Metagenomi Therapeutics (MGX) stake by 1.1% in Q2 2026, buying an estimated $6.02K and bringing the position to 400,300 shares worth $476K. The position accounts for 0.01% of the portfolio, ranked #856.

Bridgeway Capital Management first reported a position in MGX in Q3 2024 and has held it in 8 quarters since. The position peaked at $641K in Q4 2025. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Bridgeway Capital Management held 400,300 shares of Metagenomi Therapeutics worth $476K as of Q2 2026.
Bridgeway Capital Management bought 4,500 Metagenomi Therapeutics shares in Q2 2026, an estimated $6.02K.
Metagenomi Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #856 holding.
Bridgeway Capital Management first reported a position in Metagenomi Therapeutics in Q3 2024 and has held it in 8 quarters since.
Bridgeway Capital Management's Metagenomi Therapeutics position peaked at $641K in Q4 2025.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.